X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Five Prime fits squarely within Amgen's leading oncology portfolio and includes bemarituzumab, a Phase 3 trial-ready, first-in-class program for gastric cancer, the third leading cause of cancer mortality worldwide.
Lead Product(s): Bemarituzumab,Oxaliplatin,Calcium Folinate
Therapeutic Area: Oncology Product Name: FPA144
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: $1,900.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 16, 2021
Details:
Five Prime's lead asset, bemarituzumab, is a first-in-class, Phase 3 ready anti-FGFR2b antibody with positive data from a randomized, placebo-controlled Phase 2 study in frontline advanced gastric or gastroesophageal junction (GEJ) cancer.
Lead Product(s): Bemarituzumab,Oxaliplatin,Calcium Folinate
Therapeutic Area: Oncology Product Name: FPA144
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: $1,900.0 million Upfront Cash: $1,900.0 million
Deal Type: Acquisition March 04, 2021
Details:
The FIGHT trial evaluated bemarituzumab plus chemotherapy vs placebo plus chemotherapy in patients with fibroblast growth factor receptor 2b-positive , non HER2+ frontline advanced gastric or GEJ cancer. All three efficacy endpoints met pre-specified statistical significance.
Lead Product(s): Bemarituzumab,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: FPA144
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2021
Details:
FIGHT trial met all three efficacy endpoints with bemarituzumab in combination with mFOLFOX6 chemotherapy providing statistically significant and clinically meaningful improvements in progression-free survival, overall survival, and objective response rate.
Lead Product(s): Bemarituzumab,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: FPA144
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Details:
Five Prime plans to use the net proceeds of the offering to fund ongoing clinical development of bemarituzumab and FPT155, to advance FPA157 through preclinical and into clinical development, to advance its late-stage research programs and for working capital.
Lead Product(s): Bemarituzumab
Therapeutic Area: Oncology Product Name: FPA144
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cowen
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 11, 2020
Details:
All 3 efficacy endpoints in the Global Phase 2 FIGHT trial met pre-specified statistical significance. Bemarituzumab is a first-in-class therapeutic antibody targeting FGFR2b+ tumors found in approximately 30 percent of HER2- gastric cancers worldwide.
Lead Product(s): Bemarituzumab,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: FPA144
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
FPA157 is an antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced monoclonal antibody targeting CCR8 that is designed to deplete the T regulatory cell (Treg) population in the tumor microenvironment.
Lead Product(s): FPA157
Therapeutic Area: Oncology Product Name: FPA157
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
Phase 1 data illustrates the therapeutic potential of bemarituzumab as a novel approach to treating patients with FGFR2b-overexpressing gastric and gastroesophageal junction adenocarcinoma (GEA).
Lead Product(s): Bemarituzumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2020
Details:
Five Prime granted Seattle Genetics an exclusive worldwide license to a family of monoclonal antibodies and Seattle Genetics will be responsible for R&D manufacturing and marketing of ADC products.
Lead Product(s): Antibody-drug conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Seagen
Deal Size: $300.0 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement February 19, 2020
Details:
Phase 2 Trial of cabiralizumab plus opdivo (nivolumab) with and without chemotherapy in advanced pancreatic cancer did not meet primary endpoint.
Lead Product(s): Cabiralizumab,Nivolumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
